key: cord-0948287-ubljpeia authors: Pröbstel, Anne-Katrin; Schirmer, Lucas title: SARS-CoV-2-specific Neuropathology: Fact or Fiction? date: 2021-10-16 journal: Trends Neurosci DOI: 10.1016/j.tins.2021.10.006 sha: 54e56edf74efe923775a0dc3a348f53f6b148394 doc_id: 948287 cord_uid: ubljpeia Neurological symptoms and varying levels of central nervous system (CNS) immunopathology have been described in COVID-19. Recent reports suggest an increased level of innate immune activation associated with CNS border areas, as well as a compartmentalized cytokine response and dysregulated, auto-reactive CSF immune profile. However, it remains contested whether these changes reflect bystander effects of systemic inflammation or relate to CNS-specific viral infection. In this article, we summarize some of the key findings pertaining this ongoing debate and highlight directions for future investigation. Loss of smell is among the hallmark symptoms in early SARS-CoV-2 infection, and high viral load has been described in the nasal epithelium. Thus, it is conceivable that the olfactory pathway constitutes an important route of infection. Indeed, several groups have described pathological changes in the olfactory bulb of deceased COVID-19 patients, and managed to amplify virus-specific RNA along the olfactory tract in postmortem samples [2] [3] [4] . Regarding cell type specificity, several reports found evidence for infection of neuronal and other cell types including sustentacular cells of the olfactory mucosa [3, 5, 6] . Presence of SARS-CoV-2 in neuroglial cells of the olfactory tract has been demonstrated by qRT-PCR [2] [3] [4] [6] [7] [8] and cell typespecific assays such as in situ hybridization [3, 8] and immunohistochemistry [3] [4] [5] for virus-specific N (nucleocapsid) [2, 4, 7, 8] and S (spike) [2] [3] [4] [5] 8 ] RNA transcripts and proteins. Further, presence of the SARS-CoV-2-specific entry proteins ACE2 [2, 3, 5] and TMPRSS2 [5] has been described in neuroglial cells along the olfactory pathway. Other CNS regions and border areas in which SARS-CoV-2-specific virus RNA has been detected are brainstem [2, 4, [7] [8] [9] [10] including cranial nerves [4] , choroid plexus (CP) and (sub)ependymal regions [2, 4, [9] [10] [11] . Many of these areas are in close vicinity to cerebrospinal fluid (CSF) spaces, suggesting a link between presence of SARS-CoV-2 in the CSF and brain infection (Figure 1) . Notably, studies in brain organoids and postmortem COVID-19 brains have reported the presence of SARS-CoV-2related transcripts in CP epithelial and ependymal cells of the ventricles [11, 12] , both of which strongly express ACE2, relative to neurons or other glial cell types [10] [11] [12] . The CP is a highly vascularized area with an important blood-brain-and blood-CSF Apart from the question of which CNS cell types are more susceptible to SARS-CoV-2 infection, it is crucial to better understand the extent and chronicity of brain inflammation as a consequence of peripheral infection and concomitant immune activation is key in acute and chronic COVID-19. Over the last year, most neuropathological case studies found evidence for increased innate immune activation related to microglia and astrocytes. Specifically, these cell types expanded in numbers and showed morphological signs of reactivity (Figure 1) . These signs of reactivity appeared to be stronger than in patients who died under similar septic conditions. In particular, COVID-19 related microglia and perivascular macrophages were characterized by activation markers related to antigen presentation (HLA-DR, CD74) [2, 10] and phagocytosis (CD68, CD163) [2, 4, [8] [9] [10] based on conventional immunohistochemistry [2, 4, 8] , cell type-specific in situ hybridization [2] , and multiplex imaging mass cytometry [9] . Notably, several studies reported the presence of microglial nodules in the inflamed parenchyma of COVID-19 brains, pointing towards a specific compartmentalized feature of innate immune pathology in a subset of cases [8, 9] . Further, various studies found little evidence for increased number of T lymphocytes [2, 4] in the brain parenchyma of COVID-19 patients, but reported the occasional presence of cytotoxic T cells in the proximity of microglial nodules [8] [9] [10] . While the presence of severe hypoxia and hemorrhagic brain damage due to COVID-19 is contested, there is robust evidence for mild hypoxic/ischemic injury in several gray matter areas across the population of COVID-19 patients [7, 8] . In summary, these findings support the hypothesis that in most if not all cases, COVID-19 neuropathology is not related to a massive blood-brain-barrier (BBB) breakdown, severe vascular pathology, or profound diapedesis of blood-borne immune cells. However, enhanced activation of innate immune cells coupled with the presence of microglial nodules appears to be relatively prevalent, and it seems feasible that these changes could contribute to long-term damage and neuropsychiatric sequelae. Mounting evidence further suggests an important role for the adaptive immune response in COVID-19 patients with neurological symptoms. In that regard, a specific J o u r n a l P r e -p r o o f Journal Pre-proof expansion of dedifferentiated monocytes and exhausted T helper cells has been described in a recent single-cell RNA-sequencing study of COVID-19 CSF [13] . Notably, comparison of CSF from COVID-19 patients to viral encephalitis patients (from causes other than COVID-19) yielded a lower expression of multiple canonical interferon signaling transcripts across different immune cell types. This was most pronounced in severe COVID-19 cases suggesting a curtailed interferon response in the CSF [13] . Further, recent data identified a link between encephalopathy and BBB impairment in COVID-19 patients as a result of peripheral inflammation and/or hypoxia leading to the activation of neurovascular unit cells [14] . Regarding evidence for a compartmentalized CNS immune response, analysis of T cell receptor sequences in the CSF and blood revealed a clonal expansion of unique CD4 T cell clones in the CSF that were, however, not shared between COVID-19 patients [13] . Moreover, analysis of CSF B cells and antibody reactivity profiles showed distinct CSF plasma cell clusters in COVID-19 patients compared to controls, as well as a divergent anti-SARS-CoV-2 antibody profile between the CSF and plasma of the same individuals. Lastly, recombinant expression of CSF B cell receptors in COVID-19 individuals yielded reactivity to neural antigens including cross-reactivity between the immunodominant SARS-CoV-2 spike protein and neural tissue, with evidence for intrathecal production of anti-neural autoantibodies [15] . Taken together, these data suggest a compartmentalized B and T cell response to CNS antigen in a subset of patients with neurological symptoms that cannot be solely explained by BBB impairment. However, more work is needed to confirm a CSF-specific immune signature in COVID-19 patients. 2021) 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records Correlates of critical illness-related encephalopathy predominate postmortem COVID-19 neuropathology Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 Neuropathology of patients with COVID-19 in Germany: a post-mortem case series Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters Neuropathological Features of Covid-19 COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T cell interactions Dysregulation of brain and choroid plexus cell types in severe COVID-19 Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19 SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms The authors declare no competing interests in relation to this work.